Assenagon Asset Management S.A. Has $20.29 Million Stock Position in Cabot Co. (NYSE:CBT)

Assenagon Asset Management S.A. boosted its holdings in Cabot Co. (NYSE:CBT - Free Report) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 181,551 shares of the specialty chemicals company's stock after acquiring an additional 54,435 shares during the quarter. Assenagon Asset Management S.A. owned 0.33% of Cabot worth $20,292,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. First Citizens Bank & Trust Co. lifted its holdings in shares of Cabot by 2.1% during the third quarter. First Citizens Bank & Trust Co. now owns 5,426 shares of the specialty chemicals company's stock valued at $606,000 after acquiring an additional 109 shares during the period. EverSource Wealth Advisors LLC boosted its position in Cabot by 33.4% in the second quarter. EverSource Wealth Advisors LLC now owns 475 shares of the specialty chemicals company's stock valued at $48,000 after buying an additional 119 shares in the last quarter. UMB Bank n.a. boosted its position in Cabot by 53.9% in the third quarter. UMB Bank n.a. now owns 371 shares of the specialty chemicals company's stock valued at $41,000 after buying an additional 130 shares in the last quarter. Miller Howard Investments Inc. NY grew its stake in Cabot by 4.4% during the second quarter. Miller Howard Investments Inc. NY now owns 3,162 shares of the specialty chemicals company's stock worth $291,000 after buying an additional 132 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Cabot by 35.6% during the third quarter. CWM LLC now owns 564 shares of the specialty chemicals company's stock worth $63,000 after buying an additional 148 shares in the last quarter. Institutional investors and hedge funds own 93.18% of the company's stock.

Insider Buying and Selling

In other Cabot news, EVP Jeff Ji Zhu sold 1,201 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $106.19, for a total value of $127,534.19. Following the transaction, the executive vice president now owns 96,000 shares of the company's stock, valued at approximately $10,194,240. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Jeff Ji Zhu sold 1,201 shares of the company's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $106.19, for a total value of $127,534.19. Following the completion of the sale, the executive vice president now owns 96,000 shares in the company, valued at $10,194,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Sean D. Keohane sold 25,617 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total transaction of $2,601,406.35. Following the sale, the chief executive officer now owns 331,174 shares in the company, valued at $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,939 shares of company stock valued at $7,308,812 over the last three months. Company insiders own 3.07% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on CBT. JPMorgan Chase & Co. increased their price target on Cabot from $95.00 to $105.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 7th. UBS Group decreased their target price on Cabot from $103.00 to $98.00 and set a "neutral" rating on the stock in a report on Tuesday, August 6th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $101.75.

Cabot Trading Down 1.0 %

NYSE:CBT traded down $1.13 on Friday, hitting $109.26. 264,720 shares of the stock were exchanged, compared to its average volume of 331,858. The stock has a market capitalization of $6.04 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 0.93 and a beta of 1.19. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.45 and a current ratio of 2.22. Cabot Co. has a 52 week low of $65.10 and a 52 week high of $117.14. The company's 50-day moving average price is $107.40 and its 200 day moving average price is $100.27.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. Cabot had a net margin of 12.05% and a return on equity of 26.99%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm posted $1.42 earnings per share. Cabot's revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities research analysts forecast that Cabot Co. will post 7.07 earnings per share for the current year.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.